Checkpoint Therapeutics Inc. (CKPT): Prakiraan volume dodolan
Diversification through targeted lung and skin therapies reduces risks for Checkpoint Therapeutics (CKPT). The organization's projected sales demonstrate stability, with the current figure standing at 0.00. Financial potential is supported by inelastic demand and the uniqueness of cosibelimab, while a strong reputation within the oncology community due to accessible antibodies strengthens investor confidence in the brand's clinical profile.
Rincian analitis perusahaan Checkpoint Therapeutics
- kuotasi lan prakiraan analis:
- data kapitalisasi bursa:
- informasi kapitalisasi buku:
- indikator beban utang lan likuiditas:
Utang marang Ekuitas Checkpoint Therapeutics|CKPT - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Checkpoint Therapeutics, Inc|CKPT - Gunggung tanggungan utang perusahaan|Rasio utang marang kapitalisasi buku Checkpoint Therapeutics Inc.|CKPT - Utang jangka dawa|Utang jangka cendhak perusahaan Checkpoint Therapeutics|Likuiditas cepet checkpointtx.com
- statistik bathi lan rasio pasar:
CKPT - Bathi perusahaan|Bathi mangsa ngarep Checkpoint Therapeutics|CKPT - Rasio rega pasar marang bathi resik|Prakiraan rega marang bathi Checkpoint Therapeutics, Inc.|CKPT - Koefisien bali modal nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Checkpoint Therapeutics Inc.|CKPT - Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|Bathi resik saben saham (EPS TTM) Checkpoint Therapeutics|CKPT - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan checkpointtx.com|CKPT - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Checkpoint Therapeutics
- data dodolan lan asil:
Pambiji fundamental perusahaan:CKPT Checkpoint Therapeutics
Checkpoint Therapeutics specializes in developing immuno-oncology agents through strategic alliances with TG Therapeutics and scientific centers. This indicator reflects the aggregate expected revenue from the future commercialization of these developments. By analyzing the company's future sales performance, an investor assesses the monetization potential of joint clinical trials. The metric measures the business model's resilience to market shocks. It serves as the fundamental basis for calculating the fair value of assets.
Pesaing Checkpoint Therapeutics (CKPT)
Prakiraan volume dodolan ONC|Volume dodolan mangsa ngarep perusahaan halozyme.com HALO|Prakiraan volume dodolan RVMD (Revolution Medicines, Inc.)|Pendapatan mangsa ngarep perusahaan AAPG|CG Oncology Corp - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan UroGen Pharma Corp|BCAX: Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan personalis.com|Prakiraan pendapatan perusahaan Erasca|Prakiraan volume dodolan Delcath Systems Inc|Prakiraan pendapatan perusahaan YmAbs (YMAB)|AURA: Pendapatan sing dikarepake perusahaan|Prakiraan pendapatan perusahaan Candel Therapeutics, Inc. CADL|accuray.com (ARAY) - Volume dodolan sing dikarepake perusahaan|SELLAS Life Sciences Group Inc. - Prakiraan volume dodolan|Dodolan mangsa ngarep perusahaan Actuate Therapeutics Inc. ACTU|Citius Oncology, Inc (CTOR) - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan HURA|Volume dodolan mangsa ngarep perusahaan TARA|FATE (fatetherapeutics.com) - Prakiraan volume pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Pendapatan mangsa ngarep perusahaan|Champions Oncology, Inc. - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume pendapatan perusahaan XBIT (XBiotech Inc)|CEL-SCI Corp - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan OSTX (ostherapies.com)|RADX: Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Artiva Biotherapeutics (ARTV)|Prakiraan pendapatan perusahaan Adlai Nortye Ltd|VERU: Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan TPST|Prakiraan volume dodolan xiliotx.com (XLO)|Prakiraan pendapatan perusahaan Renovaro RENB|MURA (Mural Oncology PLC) - Pendapatan sing dikarepake perusahaan|Kairos Pharma Inc - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan OnKure Therapeutics Inc|GDTC (w2.cytomed.sg) - Volume dodolan mangsa ngarep perusahaan|Curis (CRIS) - Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan APLM|THAR (Tharimmune Inc) - Prakiraan volume pendapatan perusahaan|Prakiraan volume dodolan ADVB|Dodolan mangsa ngarep perusahaan Genprex Inc|Prakiraan volume dodolan CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Volume dodolan mangsa ngarep perusahaan|XBIO - Prakiraan pendapatan perusahaan|Dodolan mangsa ngarep perusahaan Salarius Pharmaceuticals Inc SLRX|PPBT: Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan American Oncology Network, Inc.|Prakiraan pendapatan perusahaan BeiGene, Ltd.|Prakiraan volume dodolan Elevation Oncology Inc.|Prakiraan pendapatan perusahaan iCAD, Inc. (ICAD)|IKNA: Pendapatan sing dikarepake perusahaan|Notable Labs Inc. - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume pendapatan perusahaan VIRX (Viracta Therapeutics Inc.)|MorphoSys AG - Prakiraan volume dodolan|nayabiosciences.com (NAYA) - Volume dodolan mangsa ngarep perusahaan|AAPGV: Prakiraan volume dodolan
